Sensex, Nifty rise for 4th straight session; pharma, banking stocks gain

Over the last four sessions, the Sensex has gained 1,248.90 points or 2.58 per cent.

BSE, sensex, market, shares, stocks, trading, brokers, investment, investors, growth, results, Q, earnings
On Monday, L&T was the top gainer in the Sensex pack, rallying over 4 per cent, followed by Dr Reddy's, Sun Pharma, NTPC, PowerGrid, IndusInd Bank, ONGC and M&M
Press Trust of India Mumbai
2 min read Last Updated : May 10 2021 | 11:50 PM IST
Equity gauges Sensex and Nifty rallied for the fourth straight session on Monday on hectic buying in mainly pharma, power and banking shares as investors brushed aside concerns over rising coronavirus cases amid positive global cues.

At the closing bell, the 30-share BSE index quoted 295.94 points or 0.60 per cent higher at 49,502.41. Over the last four sessions, the Sensex has gained 1,248.90 points or 2.58 per cent.

Similarly, the broader NSE Nifty jumped 119.20 points or 0.80 per cent to 14,942.35 – taking its total gains over the four days to 445.85 points or 3.07 per cent. On Monday, L&T was the top gainer in the Sensex pack, rallying over 4 per cent, followed by Dr Reddy's, Sun Pharma, NTPC, PowerGrid, IndusInd Bank, ONGC and M&M.

On the other hand, UltraTech Cement, Infosys, Reliance Industries, HCL Tech and Axis Bank were five losers among the 30 shares.

Sectorally, BSE metal, capital goods, healthcare, power, utilities and industrials indices rose up to 3.53 per cent, while IT was in the red.

Broader midcap and smallcap indices rallied up to 0.97 per cent.

"Domestic equities continued to defy concerns of rising Covid-19 cases and extended mobility restrictions by several states by extending gains for the fourth consecutive trading day," said Binod Modi Head-Strategy at Reliance Securities.

Favourable global cues, steady March quarter earnings along with favourable commentary, liquidity support announced by the RBI and absence of nationwide lockdown have aided domestic equities to shrug off rising COVID-19 cases in the country, he further noted.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Markets Sensex Niftystock market tradingPharma stocksBanking stocksbanking shares

Next Story